Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINNBLADDER 10
2024-516320-33-00Phase 3Authorised
- Sponsor
- Turku University Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of BCG MEDAC and UGN-103 in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Turku University Hospital. Primary endpoint: Recurrence-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
BCG MEDACUGN-103
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2024-516320-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516320-33-00.